Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Cash & Current Investments of $177.0 million for Q1 2026, up 8.88% year-over-year from $162.6 million in Q1 2025, and down 41.5% quarter-over-quarter from $302.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Cash & Current Investments data on file, last reported at $177.0 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $177.0 million, up 8.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $177.0 million (up 8.88% YoY), and the FY2025 annual result was $302.6 million, up 74.42% from the prior year.
- Cash & Current Investments declined to $177.0 million in Q1 2026 per AMRN's latest filing, from $302.6 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $362.6 million in Q1 2022 and troughed at $50.4 million in Q3 2023.
- A 5-year average of $198.7 million and a median of $173.5 million in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments sank 85.99% in 2022, then jumped 506.86% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $92.2 million in 2022, then soared by 32.22% to $121.9 million in 2023, then soared by 42.28% to $173.5 million in 2024, then soared by 74.42% to $302.6 million in 2025, then plunged by 41.5% to $177.0 million in 2026.
- Business Quant data shows AMRN's Cash & Current Investments at $177.0 million in Q1 2026, $302.6 million in Q4 2025, and $164.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.38 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 177.00 Mn |
| Dec 31, 2025 | 302.59 Mn |
| Sep 30, 2025 | 164.10 Mn |
| Jun 30, 2025 | 298.70 Mn |
| Mar 31, 2025 | 162.56 Mn |
| Dec 31, 2024 | 173.48 Mn |
| Sep 30, 2024 | 305.69 Mn |
| Jun 30, 2024 | 306.60 Mn |
| Mar 31, 2024 | 94.76 Mn |
| Dec 31, 2023 | 121.93 Mn |
| Sep 30, 2023 | 50.37 Mn |
| Jun 30, 2023 | 80.42 Mn |
| Mar 31, 2023 | 304.37 Mn |
| Dec 31, 2022 | 92.22 Mn |
| Sep 30, 2022 | 67.12 Mn |
| Jun 30, 2022 | 313.23 Mn |
| Mar 31, 2022 | 362.61 Mn |
| Dec 31, 2021 | 454.13 Mn |
| Sep 30, 2021 | 479.20 Mn |
| Jun 30, 2021 | 185.83 Mn |